A national epidemiological study of Myasthenia Gravis in Australia

European Journal of Neurology

Volumn 19, Issue 11, 2012, Pages 1413-1420

  Gattellari, M ^a   Goumas, C ^a   Worthington, J M ^a,b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b INGHAM INSTITUTE FOR APPLIED MEDICAL RESEARCH   (Australia)

^c Stroke and Neurology Services   (Australia)

Author keywords

Epidemiology; Incidence; Myasthenia Gravis; Prevalence

Indexed keywords

PYRIDOSTIGMINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CHILD; DRUG DOSE TITRATION; FEMALE; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; NORWAY; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; TAIWAN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AUSTRALIA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; SEX DISTRIBUTION; YOUNG ADULT;

EID: 84867716506     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03698.x     Document Type: Article

References (38)

1. McGrogan A, Sneddon S, de Vries CS. The incidence of Myasthenia Gravis: a systematic review. Neuroepidemiology 2010; 34: 171-183.
2. Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population-based epidemiological studies of myasthenia gravis. BMC Neurol 2010; 10: 46.
3. Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurology 2008; 7: 451-458.
4. Singer W, Opfer-Gehrking TL, McPhee BR, et al. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthoststic hypotension. J Neurol Neurosurg Psychiatry 2003; 74: 1294-1298.
5. Bharucha AE, Camilleri M, Burton D, et al. Pilot study of pyridostigmine in constipated patients with autonomic neuropathy. Clin Auton Res 2008; 18: 194-202.
6. Althausen PL, Gupta MC, Benson DR, Jones DA. The use of neostigmine to treat postoperative ileus in orthopaedic spinal patients. J Spinal Disord 2001; 14: 541-545.
7. http://www.abs.gov.au (accessed 15/3/2012)
8. Dobson AJ, Kuulasmaa K, Eberle E, et al. Confidence intervals for weighted sums of Poisson estimates. Stat Med 1991; 10: 457-462.
9. Ahmad O, Bosch-Pinto C, Lopez AD, et al. Age Standardization of Rates: A New WHO Standard. Geneva: World Health Organization, 2001.
10. Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med 1997; 16: 791-801.
11. Lai CH, Tseng HF. Nationwide population-based epidemiological study of myasthenia gravis in Taiwan. Neuroepidemiology 2010; 35: 66-71.
12. Andersen JB, Engeland A, Owe JF, et al. Myasthenia Gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol 2010; 17: 1445-1450.
13. SAS Institute Inc. SAS Software, Version 9.2 for Windows. Copyright© 2008, Cary, NC, USA: SAS Institute Inc.
14. Dean AG, Dean JA, Coulombier D, et al. Epi Info, Version 6: A Word Processing, Database, and Statistics Program for Public Health on IBM-Compatible Microcomputers. Atlanta, Georgia, USA: Centers for Disease Control and Prevention, 1996
15. Casetta I, Groppo E, De Gennaro R, et al. Myasthenia gravis: a changing pattern of incidence. J Neurol 2010; 257: 2015-2019.
16. Somnier FE, Keiding N, Paulson OB. Epidemiology of myasthenia gravis in Denmark: a longitudinal and comprehensive population survey. Arch Neurol 1991; 48: 733-739.
17. Vincent A, Clover L, Buckley C, et al. Evidence of under-diagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003; 74: 1105-1108.
18. Pallaver F, Riviera AP, Piffer S, et al. Change in myasthnia gravis epidemiology in Trento, Italy, after twenty years. Neuroepidemiology 2011; 36: 282-287.
19. Aragonés JM, Bolibar I, Bonfill X, et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003; 60: 1024-1026.
20. Meyer A, Levy Y. Chapter 33: Geoepidemiology of myasthenia gravis. Autoimmun Rev 2010; 9: A383-A386.
21. Oh SJ, Dhall R, Young A, et al. Statins may aggravate myasthenia gravis. Muscle Nerve 2008; 38: 1101-1107.
22. Ööpik M, Kaasik AE, Jakobsen J. A population based epidemiological study on myasthenia gravis in Estonia. J Neurol Neurosurg Psychiatry 2003; 74: 1638-1643.
23. MacDonald BK, Cockerell OC, Sander WAS, et al. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000; 123: 665-676.
24. Heldal AT, Owe JF, Gilhus NE, Romi F. Sero-positive myasthenia gravis: a nationwide epidemiological study. Neurology 2009; 73: 150-151.
25. Niks EH, Kuks JBM, Vershuuren JGM. Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in the Netherlands. J Neurol Neurosurg Psychiatry 2007; 78: 417-418.
26. Wirtz PW, Nijnuis MG, Sotodeh M, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 2003; 250: 698-701.
27. Tsinzerling N, Lefvert AK, Matell G, Pirskanen-Matell R. Myasthenia gravis: a long term follow-up study of Swedish patients with specific reference to thymic histology. J Neurol Neurosurg Psychiatry 2007; 7: 1109-1112.
28. Kalb B, Matell G, Pirskanen R, Lambe M. Epidemiology of Myasthenia gravis: a population-based study in Stockholm, Sweden. Neuroepidemiology 2002; 21: 221-225.
29. Grob D, Brunner N, Namba R, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008; 37: 141-149.
30. Guidetti D, Sabadini M, Bondavalli M, et al. Epidemiological study of myasthenia gravis in the province of Reggio Emilia, Italy. Eur J Epidemiol 1998; 14: 381-387.
31. Mantegazza R, Beghi E, Pareyson D, et al. A multi-centre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol 1990; 237: 339-344.
32. Christensen PB, Jensen TS, Tsiropoulos I, et al. Incidence and prevalence of myasthenia gravis in western Denmark: 1975-1989. Neurology 1993; 43: 1779-1783.
33. Beghi E, Antozzi C, Batocchi AP, et al. Prognosis of myasthenia gravis: a multicentre follow-up study of 844 patients. J Neurol Sci 1991; 106: 213-230.
34. Kuppersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol 2005; 89: 1330-1334.
35. Beekman R, Kuks JBM, Oosterhuis HJGH. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol 1997; 24: 112-118.
36. Oosterhuis HJGH. The natural course of myasthenia gravis: a long-term follow-up study. J Neurol Neurosurg Psychiatry, 1989; 52: 1121-1127.
37. Allen JA, Scala S, Jones HR. Ocular myasthenia gravis in a senior population: diagnosis, therapy and prognosis. Muscle Nerve 2010; 41: 379-384.
38. Reddel SW. Treatment of myasthenia gravis. Australian Prescriber 2007; 30: 156-160.